Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02013791 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT02013791 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 55 participants.
The verdict
NCT02013791, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1. No patients participating in Stage 1 will participate in Stage 2 of this study. This study was terminated and Stage 2 of the study was cancelled.
Interventions
- OTHER Sham
- DRUG Vehicle
- DRUG Cyclosporine New Ophthalmic Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2014-04-29 |
| Est. Completion | 2017-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02013791
The ClinicalTrials.gov registry entry for NCT02013791 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham is the first listed.
NCT02013791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02013791 about?
NCT02013791 is a clinical study titled "Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease". This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1. No patients participating in Stage 1 will participate in Stage 2 of this stud...
What is the current status of trial NCT02013791?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2014-04-29. Estimated completion is 2017-04-12.
What interventions are being tested in trial NCT02013791?
The interventions under investigation include: Sham (OTHER), Vehicle (DRUG), Cyclosporine New Ophthalmic Formulation (DRUG).
Who is sponsoring clinical trial NCT02013791?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.